Related Experiment Video
Updated: Nov 1, 2025
06:41
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
9.1K
Alopecia in anticoagulated patients
Marcos Arêas Marques1, Carmen Lucia Lascasas Porto1, Ana Letícia de Matos Milhomens1
1Universidade do Estado do Rio de Janeiro - UERJ, Hospital Universitário Pedro Ernesto, Unidade Docente Assistencial de Angiologia, Rio de Janeiro, RJ, Brasil.
Jornal Vascular Brasileiro
|June 28, 2021
Summary
Anticoagulant therapy can cause hair loss (alopecia), impacting patients psychologically and affecting treatment decisions. This review explores the potential causes and management strategies for this common side effect.
Area of Science:
- Pharmacology
- Dermatology
- Internal Medicine
Background:
- Alopecia is a frequent adverse effect of anticoagulant medications.
- This hair loss can significantly impact patient quality of life and treatment adherence, particularly in women.
- The underlying mechanisms of anticoagulant-induced alopecia are not fully elucidated.
Purpose of the Study:
- To review the potential mechanisms contributing to alopecia during anticoagulant therapy.
- To discuss current therapeutic approaches for managing this condition.
Main Methods:
- Literature review of existing studies on anticoagulant therapy and alopecia.
- Analysis of proposed pathophysiological pathways.
- Synthesis of information on management strategies.
Main Results:
- Several mechanisms, including hormonal and vascular changes, are hypothesized to cause alopecia.
- Management options are limited but may involve dose adjustment or alternative anticoagulants.
- Further research is needed to clarify the exact pathogenesis.
Conclusions:
- Understanding the mechanisms of alopecia is crucial for effective patient management.
- Addressing psychological impact and treatment adherence is vital.
- Development of targeted therapies for anticoagulant-induced alopecia is warranted.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
01:30Venous Thrombosis IV: Nursing Management
63
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
63
01:29Venous Thrombosis III: Interprofessional Care
74
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
74
01:24Disorders of Hemostasis
1.5K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.5K
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
39
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
39